Small-Cap Catalyst Watch: March 24th-28th

We've analyzed various filings and press releases to pinpoint the key catalysts and conferences scheduled for this week. Stay informed and stay ahead!

Companies Presenting at the New Street Research and BCG Future of Connectivity Leaders Conference – March 26, 2025:

● Altice USA (ATUS):

● Lumen Technologies (LUMN)

Companies Presenting at the Cancer Advocacy Group of Louisiana (CAGLA) NeauxCancer 2025 Conference – March 28th:

● Silexion (SLXN): Silexion will showcase its strategic vision and present recent preclinical findings from its SIL-204 program.

● Theriva Biologics (TOVX): Theriva will deliver a company presentation during the conference's Innovation track. The management team will also be available for one-on-one meetings throughout the event.

Companies Participating at the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference – March 27, 2025:

● Nektar Therapeutics (NKTR)

● Corvus Pharmaceuticals (CRVS)

● Aclaris Therapeutics (ACRS)

● InflaRx N.V. (IFRX)

● Jasper Therapeutics (JSPR)

● Centessa Pharmaceuticals (CNTB)

● VYNE Therapeutics (VYNE)

● Edesa Biotech, Inc. (EDSA)

Companies Participating at the iAccess Alpha Best Ideas Spring Investment Conference – March 25-26, 2025 (Virtual):

● Assertio Holdings (ASRT)

● Intelligent Bio Solutions (INBS)

● Cannae Holdings (CJMB)

● Intellicheck (IDN)

● Data Storage Corporation (DTST)

● NexGel (NXGL)

Companies Presenting at the American College of Cardiology's Annual Scientific Session – March 29-31, 2025 (Chicago, IL):

● Tenaya Therapeutics (TNYA): March 30: Poster on MYBPC3-Associated HCM (#129) – Whit Tingley, M.D., Ph.D. March 31: ACC Late-breaking Presentation on TN-201 Gene Therapy – Dr. Milind Desai, Cleveland Clinic.

● Milestone Pharmaceuticals (MIST): March 30 (11:42 – 11:49 AM CT): Moderated Poster Presentation on PSVT (NODE-303 trial) – James Ip, M.D., Weill Cornell Medicine. Upcoming: March 27, 2025 – FDA PDUFA Review for CARDAMYST™ (etripamil) nasal spray.

● Amarin Corporation (AMRN): March 29 (11:30 AM & 11:42 AM ET): EPA studies on Lp(a) and GLP-1 Agonist Effects – Multiple presenters.

Companies Presenting at the 2025 Cancer Advocacy Group of Louisiana (CAGLA) NeauxCancer Conference – March 28, 2025:

● Anixa Biosciences (ANIX): Presentation by Dr. Kumar: Overview of Anixa's cancer treatment programs, including CAR-T therapy for solid tumors and cancer vaccine initiatives. Updates on clinical progress and advancements in next-generation immunotherapies.

● PDS Biotechnology (PDSB): Event: Scientific Presentation Session: Innovation Track

Other Key Catalysts Expected This Week:

FBLG > Hamid Khoja, Ph.D., CSO of FibroBiologics, will present Potential Treatment of Chronic Diseases with Immune System Homeostasis at the German-Nordic Joint Extracellular Matrix Meeting on Thursday, March 27, at Otto-Krayer Haus, Freiburg, Germany.

NBTX > Dr. Saumil Gandhi will present safety and early efficacy data from a Phase 1 study of JNJ-1900 (NBTXR3) for unresectable, locoregional recurrent NSCLC at 8:00 AM EDT / 1:00 PM CET on Friday, March 28, 2025. Dr. Colette Shen will present data on safety and feasibility from a Phase 1 study of JNJ-1900 (NBTXR3) with nivolumab or pembrolizumab for lung metastases at the same time.

BCDA > A corporate update conference call will be hosted on Monday, March 31, 2025, following the presentation of A Double-blind, Randomized Controlled Trial of an Autologous Cell Therapy in Patients with HFrEF: Principal Results from the CardiAMP-HF Trial at the American College of Cardiology 2025 Scientific Sessions in Chicago on March 30, 2025.

MKZR > MacKenzie Realty Capital, Inc. announced that the Board of Directors has declared a dividend of $0.05 per common share, payable to shareholders of record as of March 31, 2025.

PRSO > Peraso plans to attend WISPAMERICA in Oklahoma City from March 24-27, 2025, to showcase its latest 60 GHz fixed wireless access (FWA) solutions. The Company aims to highlight next-generation connectivity for wireless Internet service providers (WISPs) and connect with journalists, analysts, OEMs, ODMs, and service providers.

QSI > Participation in an upcoming DNAnexus webinar on March 25, 2025, at 8 a.m. PT / 11 a.m. ET. The webinar will focus on the role of proteomics in multi-omics research and explore how integrating proteomics data with other omics datasets is driving new discoveries in disease research, including cancer.

RNXT > A new pre-clinical data abstract titled Pharmacodynamics of Intra-arterial vs. Intravenous Gemcitabine in Locally Advanced Pancreatic Cancer will be presented at the Society of Surgical Oncology (SSO) 2025 Annual Meeting. Authors include Emmanuel Zervos MD, Paula Novelli MD, and others. The ePoster (P379) will be available at the Tampa Convention Center, FL, from March 27-29, 2025.

SMTK > Smartkem will participate at SEMICON® China, held at the Shanghai New International Expo from March 26-28, 2025. Smartkem's Head of Business Development, Michelle Ouyang, will attend the conference to explore customer engagements and will be available for 1-on-1 meetings with industry representatives.

BEEM > Beam Global, together with Zero Motorcycles, will showcase the BeamPatrol™ and Zero Motorcycles DSR/X and FX bundles at major events, starting with MotoGP in Austin, Texas, on March 27, 2025. Attendees will experience high-performance electric motorcycles and sustainable, secure charging solutions.

PCSA > The company will participate in the MedInvest Biotech and Pharma Investor Conference on March 27-28, 2025, at Cooley's law office in New York City. Management will present a corporate overview on Friday, March 28th.

INAB > IN8bio will participate in the Immuno-Oncology 360° (IO360°) Conference 2025 in Boston, MA, from March 24-26. CEO William Ho will co-chair Day 2 on March 25, 2025, and present on "Tackling the Tough Questions in IO for Autoimmunity Disease." At 4:35 PM EDT, he will discuss IN8bio's INB-619 T cell engager program for oncology and autoimmune diseases.

LITM > The Company’s Board of Directors has approved a share repurchase program of up to US$10 million to enhance shareholder value. The Company plans to buy up to 4,926,476 common shares through open market purchases or other methods, subject to market conditions and securities laws. The program will begin on March 24, 2025, for one month, ending on April 24, 2025, or earlier if the maximum shares are purchased or the program is terminated.

TYGO > At NABCEP CE 2025, Tigo will host a training session, 'Commercial Applications: Design and Install for Success with Tigo,' on March 25, 2025, from 11:00 AM to 12:30 PM. The session will cover key strategies for commercial solar projects.

CLIK > On March 14, 2025, the Company entered into a Sale and Purchase Agreement to acquire a 25% equity interest in Top Spin Investment Company Limited for 2,980,000 newly issued ordinary shares. The acquisition aligns with Click’s strategy to expand through strategic acquisitions in Hong Kong’s human resources solutions sector. The deal is expected to close by March 31, 2025, subject to customary conditions.

NOTE > In February 2025, the Company signed a definitive agreement to divest Oxford Analytica and Dragonfly Intelligence for $40.0 million. The transaction, subject to regulatory approval and customary closing conditions, is expected to close by the end of March 2025. This divestment supports the Company’s strategic goals of strengthening its balance sheet, streamlining operations, and focusing on its core policy business.

VCIG > The Company will launch its AI Integrated Server on March 27th.

ADAG > The Company will present at the 11th Annual Immuno-Oncology 360⁰ Summit in Boston on March 26, 2025. The presentation, titled "ADG126 SAFEbody®: Targeting CTLA-4+ Tregs to Overcome MSS CRC Resistance," will focus on its innovative approach to addressing resistance in microsatellite stable colorectal cancer (MSS CRC).

SAG > SAG Holdings Limited (the "Company") will hold an Extraordinary General Meeting on March 31, 2025, at 10:00 a.m. Singapore time, to approve two key resolutions. The first is a special resolution to change the Company's name to "INNEOVA Holdings Limited." The second is an ordinary resolution to approve the acquisition of INNEOVA Engineering Pte Ltd by the Company’s wholly-owned subsidiary, INNEOVA Group Limited, through the allotment of 6,295,624 Ordinary Shares to the Seller, as outlined in the INNEOVA Agreement.

XCH > The Company announced the rollout of its first Virtual Point of Sale (VPOS) solution for XCharge systems. For more information on VPOS, visit booth 447 at the EV Charging Summit & Expo in Las Vegas from March 25-27, 2025.

III > Leaders from PNC Bank, Barclays, Comcast, SoulCycle, Expedia, AGCO, Acenda Integrated Health, Autocar Trucks, and other companies will join the ISG Xperience Summit, held March 25–26 at the Westin Times Square in New York. The event, hosted by Information Services Group (ISG), will focus on driving experience-led transformation using AI and new technologies, exploring how AI-powered solutions can create hyper-personalized experiences, while addressing the necessary data, security, and organizational structures for success.

AKAN > Akanda Corp. (the "Company") entered into a Share Exchange Agreement (SEA) with First Towers & Fibers Corp. (FTFC) on March 5, 2025, for a business combination. FTFC's common shares will be exchanged for Company shares or cash, with FTFC becoming a wholly owned subsidiary. The agreement can be terminated under certain conditions, such as mutual consent, failure to close by March 31, 2025, or breaches by either party. After the transaction, the Company plans to raise $4–$10 million through debt or equity financing. FTFC develops telecommunications infrastructure in Mexico, and Christopher Cooper, a director of the Company, is involved with FTFC.

CCO > The Company announced it has received all necessary regulatory clearances and approvals for the sale of its Europe-North segment to Bauer Radio Limited, a subsidiary of Bauer Media Group. The transaction remains subject to the delivery of certain closing items and is expected to close on March 31, 2025.

JFBR > Under the definitive share purchase agreement, Impact will acquire 100% of Fort Products' equity in exchange for 75.02% ownership of Impact's share capital, potentially increasing to 83.29% if certain milestones are met. The Proposed Merger is expected to be completed by May 31, 2025, subject to the satisfaction of all conditions, though there is no assurance the merger will be completed as planned.

SES > Dr. Hu will present on "AI4Safety: Enhancing BESS Safety and Longevity" at the Energy Storage Summit USA 2025 on March 26, 2025, at 5:35 pm ET. The event will take place at the Renaissance Dallas Addison Hotel in Dallas, Texas. Dr. Hu will also be available for one-on-one meetings during the summit.

NIVF > The Company provided an update on its reverse merger with European Wellness Investment Holdings Limited ("EWIHL") and acquisition of MicroSort Reproductive Technology. The merger, where EWIHL would hold 61.6% of the Company, is contingent on due diligence and delivery of EWIHL's financials by March 31, 2025. If the financials are not provided by that date, the Company can terminate the agreement.

POAI / RENB > Predictive Oncology entered into an LOI with Renovaro for an acquisition. On February 28, 2025, they amended the agreement, extending the termination date to March 31, 2025. Renovaro is purchasing 467,290 shares for $500,000 and plans to buy another 901,298 shares for $964,389 upon a definitive agreement.

DTCK > Davis Commodities Limited signed an MOU with Carfax Commodities (Asia) Pte Ltd on February 24, 2025, to explore a strategic share acquisition. The proposed transaction involves Davis Commodities acquiring up to 49% of Carfax Commodities. The due diligence process is set to be finalized by March 28, 2025.

THTX > On December 10, 2024, the Company announced that the FDA has set a Prescription Drug User Fee Act (PDUFA) action date of March 25, 2025, for its supplemental Biologics License Application for the F8 formulation of tesamorelin. If approved, the F8 formulation will replace the F4 formulation (sold as EGRIFTA SV®) and is patent-protected in the U.S. until 2033.

KAVL > The Company has entered into a Merger and Share Exchange Agreement with Delta Corp Holdings Limited, Pubco, Merger Sub, and the Sellers. If consummated, Pubco will become the parent company, and new officers and directors will be appointed by Pubco, with the Company retaining the right to appoint one director. The transactions are expected to close in March or April 2025, but there is no assurance they will close by then or at all.

LUCY > Innovative Eyewear will participate in the eMerge Americas 2025 Conference, held in Miami, FL, on March 27-28. This premier event focuses on innovation and entrepreneurship in the Americas.

BREA > Brera Holdings continues to execute its multi-step acquisition plan. Upon final closing, which has a target date of March 31, 2025, Brera Holdings will own 51.73% of the Club's issued corporate capital.

SPRC > On April 10, 2024, SciSparc and AutoMax Motors Ltd. signed a merger agreement for AutoMax to become a wholly-owned subsidiary of SciSparc. AutoMax shareholders will receive ordinary shares and warrants of SciSparc, resulting in them owning about 49.99% of SciSparc. The merger has been approved by both companies' boards and will be presented for shareholder approval. The merger completion date has been extended to March 31, 2025, following previous deferrals.

RAIN > RET is currently warehousing two fully built rain generation systems in Sydney, Australia, created by ionization engineer Scott Morris. After rigorous testing, the company plans to sign its first U.S. client contract in March 2025. RET will also hire a CTO, CFO, software engineers, electrical engineers, mechanical engineers, and weather experts. Additionally, the company will establish headquarters in Naples, FL, by March 2025 and hire a top-tier marketing firm to promote its ionization technology.

BCAB > Two abstracts have been accepted for poster presentations at the European Lung Cancer Congress (ELCC) 2025 in Paris, France, from March 26–29, 2025, and the Mayo Clinic Multidisciplinary Head and Neck Cancer Symposium 2025 in Scottsdale, AZ, from March 27–29, 2025.

IMMP > poster presentation for the pivotal TACTI-004 Phase III trial. The poster will be presented March 26th at the European Lung Cancer Congress (ELCC) 2025, taking place in Paris, France, from 26-29 March 2025.

NXU > On October 23, 2024, NXU and Verde Bioresins entered into a Merger Agreement. The merger involves two phases: Merger Sub I merges with Verde, and then Verde merges with Merger Sub II. Nxu stockholders approved the merger on February 11, 2025. The merger is expected to close by March 31, 2025. Afterward, Nxu will be renamed "Verde Bioresins, Corp." and its ticker symbol will change to "VRDE."

--

Disclaimer: All content provided by BigTimePennys Report is for informational purposes only. The information provided should not be considered as a substitute for professional advice, analysis, or guidance. Any investment decisions made based on the information provided are solely at the user's own risk. BigTimePennys Report are not liable for any losses or damages incurred as a result of using this information. BigTimePenny is not operated by a licensed broker, a dealer, or a registered investment adviser. The Securities Litigation Reform Act of 1995 provides safe harbor protection for forward-looking statements made by companies or individuals. It should be noted that any forward-looking statements made by BigTimePennys Report, its authors, are not guarantees of future performance or results. These statements are subject to risks, uncertainties, and assumptions that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. The content provided by BigTimePennys Report does not constitute an endorsement, recommendation, or solicitation to buy, sell, or hold any securities or investment products. BigTimePennys Report, its authors, do not endorse or recommend any specific investment strategies, securities, or companies. It is crucial to conduct thorough research and seek advice from a qualified professional before making any investment decisions. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. The user assumes full responsibility for the use of the information provided by BigTimePennys Report. BigTimePennys Report, its authors, disclaim any liability for any direct, indirect, or consequential damages arising from the use or reliance on the information provided. Users should exercise their own judgment and discretion when interpreting and utilizing the information provided. Please note that the content provided by BigTimePennys Report is based on available information and sources believed to be reliable. However, market conditions and regulations may change over time, and there may be inaccuracies or errors in the information provided. It is recommended to verify the information with current and reliable sources before making any investment decisions. Investing in micro-cap companies is highly speculative and carries an extremely high degree of risk. BigTimePenny is not a fiduciary by virtue of any person's use of or access to this content. We were NOT compensated for this article.